Cutler Group LP Tcr2 Therapeutics Inc. Transaction History

Cutler Group LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 18, 2022	BUY	$4.58 - $8.34 $4,580 - $8,340	1,000 New	1,000 $4,000
Q3 2021 Oct 26, 2021	SELL	$8.44 - $18.35 $5,908 - $12,845	-700 Closed	0 $0
Q2 2021 Jul 19, 2021	BUY	$16.41 - $24.71 $1,641 - $2,471	100 Added 16.67%	700 $11,000
Q1 2021 Apr 26, 2021	SELL	$20.38 - $34.07 $20,380 - $34,070	-1,000 Reduced 62.5%	600 $13,000
Q4 2020 Jan 21, 2021	BUY	$19.0 - $32.63 $24,700 - $42,419	1,300 Added 433.33%	1,600 $49,000
Q3 2020 Oct 27, 2020	SELL	$13.1 - $20.69 $10,480 - $16,552	-800 Reduced 72.73%	300 $6,000
Q2 2020 Jul 22, 2020	BUY	$6.51 - $16.85 $7,161 - $18,535	1,100 New	1,100 $16,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.